Meet the brightest minds advancing ovarian
cancer research

Top of page

At Lena Wäppling’s Foundation, we believe ovarian cancer is a global women’s health issue and that’s why we award funds to science-led research projects across the globe. Over 70% of ovarian cancer cases are detected at later stages (stage 3 and 4), underscoring the critical need for early intervention.

The risk of recurrence is very high, with approximately 80% of those affected experiencing a relapse within two years after completing treatment.

Early diagnosis is paramount, as survival rates increase dramatically when the disease
is detected in its earliest stages. The high risk of recurrence in ovarian cancer is a fact that needs more attention, as the disease often returns and requires repeated treatment interventions. With each recurrence, treatment options become fewer, and eventually, no effective alternatives remain.

By funding ovarian cancer research, we hope that scientists can identify biomarkers, gain a deeper understanding of disease progression and risk factors, and discover more effective treatment methods. This paves the way for a future where ovarian cancer is no longer a life-threatening disease.

Each year brings us closer to realizing our vision

2024

A total
sum of SEK
1.2 million
was awarded

2023

A total sum
of SEK
1.1 million
was awarded

2022

A total
sum of
SEK 1 million
was awarded

2021

A total sum
of SEK
1 million
was awarded

2020

A total
sum of
SEK 500.000
was awarded

Since 2019, we have distributed 4.3 million euros/SEK
4.8 million to researchers at leading universities and institutes, advancing the forefront of research against this deadly disease.

Find out more about our recipients below

Angelique Flöter-Rådestad, Associate Professor , Karolinska Institutet, Stockholm

Interview

Project: BRCA mutation associated ovarian and breast cancer: evaluation of early detection markers and strategies for prevention

Many cases of ovarian cancer are not diagnosed until the disease has progressed to an advanced stage (Stage III or IV), when it has spread beyond the ovaries. In these later stages, symptoms become more pronounced, but the cancer is also more difficult to treat effectively.
That’s because ovarian cancer often doesn't cause any noticeable symptoms in its early stages which makes early diagnosis a significant challenge.

There is currently no widely accepted and effective screen for women who might be at risk although women with inherited BRCA mutations have a substantially higher lifetime risk of developing ovarian cancer.

This study evaluates BRCA mutation as early detection markers to inform strategies for prevention.

Claudia Mateoiu, Sahlgrenska University Hospital, Göteborg

Project: Comparative studies of genetic abnormalities between endometriosis and ovarian cancer development

Endometriosis, a condition where endometrial-like tissue grows outside the uterus, has been associated with an increased risk of developing certain types of ovarian cancer, particularly endometrioid and clear cell ovarian carcinomas.

By exploring the genetic similarities and differences between endometriosis and ovarian cancer, the project aims to gain a deeper understanding of the molecular links between these two conditions, ultimately contributing to earlier detection, improved risk assessment, and the development of more effective preventive and therapeutic strategies for women at risk of or affected by these diseases.

Xiaonan Zhang, Uppsala University, Uppsala

Interview

Marta Lomnytska, Uppsala University, Uppsala

Interview

Twana Alkasalias, Karolinska Institutet, Stockholm

Interview

Project: Overcoming drug resistance and relapse by targeting quiescent cancer cell populations in ovarian clear cell carcinoma

One of the major challenges in treating ovarian cancer is that it develops resistance to standard chemotherapy. It is believed that a subpopulation of cancer cells enter a dormant or quiescent state, which makes these quiescent cells “survive” chemotherapy and later lead to disease relapse. When patients experience relapse, the cancer is more aggressive and resistant to further treatment.

Zhang’s research aims to investigate strategies to eliminate these dormant
cells to overcome drug resistance and relapse to potentially achieve durable remission for ovarian cancer.

Project: Platelet protein markers on microvesicles for differential diagnostic of adnexal lesions and cancer

Currently, differential diagnosis between benign and malignant lesions often relies on imaging techniques and invasive surgical biopsies. Adnexal lesions refer to abnormal growths or masses that develop in ovaries, fallopian tubes and surrounding tissues. Some lesions can be benign while others may be cancerous. Distinguishing between benign and malignant lesions
is crucial for early and accurate diagnosis for ovarian cancer.

Lomnytska's research project aims to identify and confirm protein markers that can reliably differentiate between benign and malignant lesions, which could lead to the development of a minimally invasive diagnostic test for ovarian cancer.

Project: PREvention and Prediction of ovarian-and breast cancer – PREP

Cancer is often characterized by the accumulation of mutations in genes, which can affect their functioning. However, there are certain surveillance mechanisms in the body that prevent the growth of cancer cells. He also discusses the role of hormone-responsive organs like the breast and ovaries in cancer development, particularly in individuals
with mutations in the BRCA genes.

This study hopes to build better understanding around why people develop cancer while others don’t to help prevent and predict ovarian and breast cancer.

Josefin Fernebro, Karolinska Institutet, Stockholm

Interview

Björg Jónsdóttir, Uppsala University, Uppsala

Project: [11C]AZ14193391 - PET as a selection tool for treatment with PARP inhibitors in patients with meta-static ovarian cancer

PET scans can detect metastatic sites with high sensitivity essential for determining the extent of the disease and planning treatment strategies. By assessing changes in metabolic activity, clinicians can determine if the cancer
is responding to therapy. Tumors that show high metabolic activity or certain imaging characteristics may be more susceptible to PARP inhibitors. By using
PET to select patients who are likely to respond to PARP inhibitors, clinicians can avoid administering these drugs to patients who are unlikely to benefit, thus sparing them from potential side effects and ineffective treatments.

PET can serve as a valuable tool in guiding personalized treatment of ovarian cancer by accurately staging ovarian cancer, monitoring treatment response and identifying suitable candidates for PARP inhibitors

Project: Early detection of relapse in ovarian cancer using home-sampling and
a multiplex protein biomarker test – a pilot study

A multiplex protein biomarker test can measure several proteins associated with ovarian cancer to improve diagnostic accuracy and provide detailed biomarker profiles that can help tailor treatments to individual patients’ needs.

An at-home biomarker test allows for timely identification of cancer recurrence, potentially leading to earlier intervention and improved patient outcomes.

Interview

Project: Effect of anesthetic agents, propofol vs inhalational anesthetics, on long-term survival after surgery for ovarian cancer: a population-based registry study.

This study explores how the choice of anesthesia can potentially inform anesthesia practices to improve long-term survival rates for ovarian cancer patients.

Understanding the relationship can potentially inform anesthesia practices to improve long-term survival rates for ovarian cancer patients.

Mats Enlund, Uppsala University, Uppsala

Interview

Tobias Sjöblom, Professor, Uppsala University, Uppsala

Interview

Stefan Enroth, Associate Professor, Uppsala University, Uppsala

Project: Discovery and validation of diagnostic biomarkers for ovarian cancer

Ovarian cancer is often referred to as a "silent killer" because it rarely exhibits noticeable symptoms in its early stages. By identifying reliable biomarkers, ovarian cancer could potentially be detected earlier, when treatment is more effective and survival rates are higher. These biomarkers can lead to discovery of new targeted therapies and also to monitor treatment response and disease progression, guiding treatment strategies.

The discovery and validation of diagnostic biomarkers for ovarian cancer represent a critical step towards improving early detection, enhancing diagnostic accuracy, enabling personalized treatment strategies, and ultimately reducing the high mortality rates associated with this devastating disease.

Project: Protein biomarkers for early detection of ovarian cancer from dried, self-sampled cervico vaginal fluid

Ovarian cancer often goes undetected until later stages due to a lack of specific symptoms and effective screening methods. Biomarkers present in cervicovaginal fluid allow for the detection of ovarian cancer at an earlier, more treatable stage. Cervicovaginal fluid or cervical mucus, can be self-collected by women at home via a vaginal swab, making it more convenient, non-invasive and potentially more acceptable sampling method.

By leveraging the potential of cervicovaginal fluid biomarkers, this study hopes
to develop more effective, non-invasive and accessible methods for early detection of ovarian cancer.

Interview

Gabriel Schär, Professor, Universitäts Spital, Zürich, Switzerland

Project: Early detection of ovarian cancer in BRCA-carriers and non-carriers

Ovarian cancer is often referred to as a "silent killer" because it rarely causes symptoms in the early stages. Early detection in non-carriers can significantly improve the chances of successful treatment and increase survival rates. At the same time, ovarian cancers associated with BRCA mutations tend to develop at
an earlier age and can be more aggressive, making early detection even more critical in this high-risk group.

This study explores strategies for early detection of ovarian cancer in
BRCA-carriers and non-carriers to drive earlier diagnosis.

Ulrika Joneborg, Karolinska University Hospital, Stockholm

Interview

Project: PET imaging of malignant ovarian tumors by a novel tracer, 68Ga-FAPI-46

Positron Emission Tomography (PET) is an imaging technique used in diagnosing and monitoring cancer. It uses radioactive tracers like 68Ga-FAPI-46 that target fibroblast activation protein (FAP) that is overexpressed in tumours. By studying the mechanisms by which this tracer binds to ovarian cancer cells, researchers may gain insights into potential therapeutic targets or biomarkers that could lead to the development of new targeted therapies or diagnostic tools.

The use of a targeted PET tracer could potentially enhance visualisation and localisation of solid tumours like ovarian cancer leading to more accurate staging and improved treatment planning. It can also help in monitoring response to various treatments to help inform decisions about adjusting or changing therapeutic approaches.

The evaluation for novel PET tracers like 68Ga-FAPI-46 is an important step towards improve detection, staging and management of ovarian cancer.

Annika Strandell, Associate Professor, Sahlgrenska University Hospital, Göteborg

Project: Opportunistic salpingectomy for the prevention of ovarian cancer

Salpingectomy is the removal of fallopian tubes during pelvic surgery. Evidence suggests that a significant proportion of ovarian cancers originate from the fallopian tubes rather than the ovaries themselves. For women at high risk of developing ovarian cancer such as those with BRCA gene mutations or a strong family history,
it can serve as a risk-reducing strategy, lowering their chances of developing ovarian cancer alter in life.

The study evaluates the potentially valuable strategy for ovarian cancer prevention particularly for women at high risk.

Interview

Ingrid Hedenfalk, Professor, Lund University, Lund

Interview

Project: Single Cell Resolution of the High-Grade Serous Cancer Ecosystem

High-grade serous ovarian cancer (HGSOC) is a highly heterogenous disease, with various subtypes exhibiting distinct molecular profiles, behaviours and response sot treatment. Our understanding of the biological mechanisms underlying these different subtypes and their implications for treatments is still limited.

Single-cell resolution analysis of high-grade serous ovarian cancer provides
the opportunity to dissect the complexitiesof this disease leading to a deeper understanding of its biology paving the way for more effective diagnostic, prognostic and therapeutic strategies.

Work with us to make
surviving ovarian cancer
a normal outcome.

Apply for Grant

Support our mission to
make surviving ovarian cancer the norm.

Get Involved

Meet the brightest minds advancing ovarian cancer research

Each year brings us closer to realizing our vision

A total sum of SEK 1.2 million was awarded

A total sum of SEK 1.1 million was awarded

A total sum of SEK 1 million was awarded

A total sum of SEK 1 million was awarded

A total sum of SEK 500.000 was awarded

Since 2019, we have distributed 4.3 million euros/SEK 4.8 million to researchers at leading universities and institutes, advancing the forefront of research against this deadly disease.

Find out more about our recipients below

Work with us to make surviving ovarian cancer a normal outcome.

Support our mission to make surviving ovarian cancer the norm.

Meet the brightest minds advancing ovarian
cancer research

A total
sum of SEK
1.2 million
was awarded

A total sum
of SEK
1.1 million
was awarded

A total
sum of
SEK 1 million
was awarded

A total sum
of SEK
1 million
was awarded

A total
sum of
SEK 500.000
was awarded

Since 2019, we have distributed 4.3 million euros/SEK
4.8 million to researchers at leading universities and institutes, advancing the forefront of research against this deadly disease.

Work with us to make
surviving ovarian cancer
a normal outcome.

Support our mission to
make surviving ovarian cancer the norm.